Results from ALICE - Atezolizumab Combined with Immunogenic Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer, a Randomized Phase IIb Trial

被引：0
|
作者：
Kyte, Jon Amund
Rossevold, Andreas H.
Andresen, Nikolai K.
Bjerre, Christina Annette
Gilje, Bjornar
Jakobsen, Erik Hugger
Raj, Sunil Xavier
Falk, Ragnhild Sorum
Borgen, Elin
Jahr, Thea
Garred, Oystein
Lomo, Jon
Mathiesen, Randi Margit
Naume, Bjorn
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD11-11
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD11-11
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)
    Loibl, S.
    Rastogi, P.
    Seiler, S.
    Jackisch, C.
    Lucas, P. C.
    Denkert, C.
    Poklepovic, A.
    Moreno, F.
    Mamounas, E. P.
    Nekljudova, V.
    Lin, Y.
    Wolmark, N.
    Geyer, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S339 - S339
  • [42] Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
    Souza, Cristiano de Padua
    Carneiro, Ana Suellen Barroso
    Lessa, Ana Cecilia de Oliveira
    Lacerda, Domicio Carvalho
    Paiva, Carlos Eduardo
    Zorzetto, Marina Moreira Costa
    de Freitas, Ana Julia Aguiar
    Santana, Iara Viana Vidigal
    de Oliveira, Marco Antonio
    Palmero, Edenir Inez
    Marques, Marcia Maria Chiquitelli
    Reinert, Tomas
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (01) : 57 - 65
  • [43] Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
    Cristiano de Pádua Souza
    Ana Suellen Barroso Carneiro
    Ana Cecília de Oliveira Lessa
    Domício Carvalho Lacerda
    Carlos Eduardo Paiva
    Marina Moreira Costa Zorzetto
    Ana Julia Aguiar de Freitas
    Iara Viana Vidigal Santana
    Marco Antonio de Oliveira
    Edenir Inêz Palmero
    Márcia Maria Chiquitelli Marques
    Tomás Reinert
    Breast Cancer Research and Treatment, 2023, 202 : 57 - 65
  • [44] Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
    Tan, Antoinette R.
    Wright, Gail S.
    Thummala, Anu R.
    Danso, Michael A.
    Popovic, Lazar
    Pluard, Timothy J.
    Han, Hyo S.
    Vojnovic, Zeljko
    Vasev, Nikola
    Ma, Ling
    Richards, Donald A.
    Wilks, Sharon T.
    Milenkovic, Dusan
    Xiao, Jie
    Sorrentino, Jessica
    Horton, Janet
    O'Shaughnessy, Joyce
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 629 - 636
  • [45] IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
    Emens, Leisha A.
    Adams, Sylvia
    Loi, Sherene
    Schneeweiss, Andreas
    Rugo, Hope S.
    Winer, Eric P.
    Barrios, Carlos H.
    Dieras, Veronique
    de la Haba-Rodriguez, Juan
    Gianni, Luca
    Chui, Stephen Y.
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancer
    Jiang, Zefei
    Ouyang, Quchang
    Sun, Tao
    Zhang, Qingyuan
    Teng, Yuee
    Cui, Jiuwei
    Wang, Haibo
    Yin, Yongmei
    Wang, Xiaojia
    Zhou, Xin
    Wang, Yongsheng
    Sun, Gang
    Wang, Jingfen
    Zhang, Lili
    Yang, Jin
    Qian, Jun
    Yan, Min
    Liu, Xinlan
    Yi, Tienan
    Cheng, Ying
    Li, Man
    Zang, Aimin
    Wang, Shusen
    Wang, Chuan
    Wu, Xinhong
    Cheng, Jing
    Li, Hui
    Lin, Ying
    Geng, Cuizhi
    Gu, Kangsheng
    Xie, Chunwei
    Xiong, Huihua
    Wu, Xiaohong
    Yang, Junlan
    Li, Qingshan
    Chen, Yiding
    Li, Fanfan
    Zhang, Anqin
    Zhang, Yongqiang
    Wu, Yudong
    Nie, Jianyun
    Liu, Qiang
    Wang, Kun
    Mo, Xueli
    Chen, Lilin
    Pan, Yueyin
    Fu, Peifen
    Zhang, Helong
    Pang, Danmei
    Sheng, Yuan
    FUTURE ONCOLOGY, 2025, 21 (04) : 421 - 429
  • [47] A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC)
    Damodaran, Senthil
    Liu, Diane
    Schwartz, Jill
    Valero, Vicente
    Ramirez, David
    Saleem, Sadia
    Ueno, Naoto T.
    Ibrahim, Nuhad K.
    Karuturi, Meghan S.
    Murthy, Rashmi K.
    Moulder, Stacy
    Litton, Jennifer K.
    CANCER RESEARCH, 2023, 83 (05)
  • [48] GeparDouze/NSABP B-59: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy with atezolizumab or placebo in patients with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo
    Loibl, S.
    Jackisch, C.
    Rastogi, P.
    Seiler, S.
    Lucas, P. C.
    Denkert, C.
    Costantino, J.
    Nekljudova, V.
    Wolmark, N.
    Geyer, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [49] Durvalumab Compared to Maintenance Chemotherapy in Patients With Metastatic Breast Cancer: Results From the Phase II Randomized Trial SAFIR02-IMMUNO
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 14 - 15
  • [50] Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
    Assadipour, Yasmine
    Zacharakis, Nikolaos
    Crystal, Jessica S.
    Prickett, Todd D.
    Gartner, Jared J.
    Somerville, Robert P. T.
    Xu, Hui
    Black, Mary A.
    Jia, Li
    Chinnasamy, Harshini
    Kriley, Isaac
    Lu, Lily
    Wunderlich, John R.
    Zheng, Zhili
    Lu, Yong-Chen
    Robbins, Paul F.
    Rosenberg, Steven A.
    Goff, Stephanie L.
    Feldman, Steven A.
    CLINICAL CANCER RESEARCH, 2017, 23 (15) : 4347 - 4353
12345